EWSR1 and Ewing sarcoma: As with ARA-C treatment, doxorubicin, an agent currently used to treat patients with Ewing sarcoma, did recapitulate the EWS/FLI off signature (p = 0.01) (Figures 2C and S3I–S3L) by three days.